Alpine Immune Sciences Inc
F:34LA
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches EUR.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Alpine Immune Sciences Inc
Operating Income
Alpine Immune Sciences Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Alpine Immune Sciences Inc
F:34LA
|
Operating Income
-$51.4m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Operating Income
$19.7B
|
CAGR 3-Years
0%
|
CAGR 5-Years
9%
|
CAGR 10-Years
13%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Operating Income
$11.3B
|
CAGR 3-Years
6%
|
CAGR 5-Years
7%
|
CAGR 10-Years
-6%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Operating Income
$12.1B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Operating Income
$4.5B
|
CAGR 3-Years
2%
|
CAGR 5-Years
11%
|
CAGR 10-Years
N/A
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Operating Income
$3.9B
|
CAGR 3-Years
-17%
|
CAGR 5-Years
4%
|
CAGR 10-Years
12%
|
|
Alpine Immune Sciences Inc
Glance View
Alpine Immune Sciences Inc., a biotechnology company, stands poised at the intersection of innovation and necessity, carving its niche in the fast-paced world of immune system modulation. Founded to address the complex challenges of autoimmune inflammation and cancer, Alpine harnesses the intricate mechanisms of the immune system to develop novel therapies. The company's unique approach centers around their proprietary platform, the "Directed Evolution" technique, which enhances the body's natural defenses by evolving proteins to selectively target cells and pathways. This approach aims to balance efficacy with safety—a critical factor in immunotherapy—to not just treat but possibly transform the landscape of autoimmune and cancer treatments. In this innovative pursuit, Alpine generates revenue through a multi-pronged business model, leveraging both partnerships and proprietary product development. The company actively collaborates with big-name players in the pharmaceutical industry, securing milestone payments, and royalties that provide financial footing. Their pipeline, rich with potential candidates, further positions Alpine for future commercial success, especially as its therapies advance into later stages of clinical trials. By focusing on high-need areas and utilizing strategic collaborations, Alpine Immune Sciences is steadily building a sustainable business model while offering a beacon of hope for patients looking for more effective treatment options.
See Also
What is Alpine Immune Sciences Inc's Operating Income?
Operating Income
-51.4m
USD
Based on the financial report for Mar 31, 2024, Alpine Immune Sciences Inc's Operating Income amounts to -51.4m USD.
What is Alpine Immune Sciences Inc's Operating Income growth rate?
Operating Income CAGR 5Y
-3%
Over the last year, the Operating Income growth was 23%. The average annual Operating Income growth rates for Alpine Immune Sciences Inc have been -15% over the past three years , -3% over the past five years .